For years, we’ve looked at chronic wounds through a relatively narrow lens—clean them, debride them, and hope the host’s biology eventually kicks into gear. But as our understanding of the wound microbiome deepens, it’s becoming clear that these microbial communities aren’t just “there”—they are active architects of the healing (or non-healing) environment.
A recent review by Molasy and Wrzosek (2026) highlights a critical shift: moving from identifying “bugs” to understanding the functional ecosystem of the wound.
The Biofilm Barrier
The hallmark of chronicity is the biofilm. Found in over 80% of non-healing wounds, these resilient structures protect bacteria from both antibiotics and the host immune system.
- Tolerance: Biofilms can increase antimicrobial tolerance by up to 1,000-fold compared to free-floating (planktonic) bacteria.
- Immune Evasion: They skew the host response toward chronic inflammation, impairing neutrophil and macrophage function.
- The Shift: As a wound becomes chronic, we see a “race to the bottom” in terms of diversity—commensals are pushed out by dominant, stress-tolerant pathogens.
Precision Diagnostics: Beyond the Swab
Traditional cultures only tell about 20% of the story, often missing the fastidious anaerobes that drive chronicity. The move toward metagenomic next-generation sequencing (mNGS) and shotgun metagenomics allows us to see the full spectrum, including fungi and viruses that were previously “invisible”.
Table 1. Summary of Molecular Techniques for Microbiome Assessment
| Method | Targets | Strengths | Limitations | Clinical Utility |
| Classical Culture | Bacteria (mainly aerobes) | Antibiotic susceptibility testing | Low sensitivity (~20% yield); misses anaerobes | Risk of inappropriate empiric therapy |
| 16S rRNA Sequencing | Bacteria | Culture-independent; high community coverage | Limited to bacteria; no functional data | Improved anaerobe detection (87% vs 23% culture) |
| Shotgun Metagenomics | Bacteria, fungi, viruses | Comprehensive; profiling of AMR genes and functional pathways | High cost; complex bioinformatics | AMR gene profiling to inform stewardship |
| Metaproteomics | Expressed proteins | Profiles active virulence and host response | Costly; requires deep reference databases | Identifying active inflammation in DFUs |
Microbiome Biomarkers: Predicting the Trajectory
We are beginning to identify specific “microbial signatures” that act as red flags for stalled healing. High levels of specific anaerobic cocci or altered protease ratios can tell us a wound is in trouble before clinical signs become obvious.
Table 2. Potential Biomarkers and Their Clinical Significance
| Biomarker | Association | Clinical Relevance | Threshold / Effect |
| Anaerococcus abundance ↑↑ | Dysbiosis | Predicts delayed DFU healing | >10% relative abundance; HR 1.8 for non-healing |
| IL-1β/IL-1RA ratio ↑ | Inflammation | Distinguishes non-healing from healing | Ratio > 2.5; AUC 0.684 |
| CXCL8/CXCL10 ratio ↑ | Infection | Indicates infected/non-healing stage | Ratio > 1.8; AUC 0.767 |
| MMP-9 (Wound Fluid) ↑ | Protease burden | Predicts poor healing at baseline | High baseline levels inversely correlate with area reduction |
Emerging Therapies: Modulating the Ecosystem
If the microbiome is the driver, then we need tools to steer it back toward a “pro-healing” state.
- Probiotics & Prebiotics: Using strains like Limosilactobacillus reuteri to outcompete pathogens and speed up wound closure.
- Phage Therapy: Specifically targeting multidrug-resistant bacteria and penetrating deep into biofilms.
- Topical Oxygen (TOT): Beyond just “breathing” life into tissue, TOT reduces anaerobic populations by 60%, effectively reshaping the microbial landscape.
The Bottom Line
The “one-size-fits-all” approach to wound care is fading. By integrating microbiome profiling with clinical assessment, we can move toward stratified management—intervening earlier and more accurately to prevent the devastating outcomes of chronic wounds.
Leave a Reply